INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC
First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.
HexAgon-HN Trial Highlights The combination of the OX40 agonist INBRX-106 and pembrolizumab generated a higher ORR and a higher increase in CD8- and CD4-positive T-cell proliferation and activation compared with pembrolizumab monotherapy in patients with treatment-naive, PD-L1–positive HNSCC.Preliminary data show a manageable safety profile for the combination regimen, with no treatment-related deaths and common adverse effects being mostly low-grade.Progression-free survival data and the initiation of the phase 3 portion of the trial are expected in late 2026.
comments(0)
5-min edit window · permanent after that